In this article, I’ll be looking once again at German company Evotec (NASDAQ:EVO) (OTCPK:EVOTF) – a business in the drug ...

Novo Nordisk will provide Variant with an upfront payment and additional near-term R&D funding that could reach up to $50m.

Not Disclosed Neuroscience and Pain 2 is under clinical development by Evotec and currently in Phase I for Unspecified Neurologic Disorders.

Evotec SE (NASDAQ:EVO – Get Free Report) gapped up before the market opened on Thursday . The stock had previously closed at $4.16, but opened at $4.32. Evotec shares last traded at $4.29, with a ...

German stocks are a bit subdued Tuesday morning with investors making cautious moves amid a lack of significant triggers. Data on ...

AbbVie, Calico and Denali Therapeutics’ hopes of treating amyotrophic lateral sclerosis (ALS) by targeting eIF2B have all ...

The issuer is solely responsible for the content of this announcement. Novo Nordisk and Evotec select three projects from Boston University, Harvard University in collaboration with Mass General ...

Evotec SE (Frankfurt Stock Exchange:EVT)(SDAX/TecDAX, ISIN: DE0005664809)(NASDAQ:EVO) announced that its translational drug discovery accelerator with Novo Nordisk, LAB eN², which aims to nurture ...

EVT-401 is under clinical development by Evotec and currently in Phase I for Rheumatoid Arthritis. According to GlobalData, Phase I drugs for Rheumatoid Arthritis have a 69% phase transition success ...

QUANTRO’s proprietary time-resolved functional transcriptomic discovery platform accelerates target screening for complex indications in oncology ...